Results 1 to 10 of about 19,471 (205)

Carvedilol Exerts Cardioprotective Effects Against Doxorubicin Toxicity via Autophagy Modulation and Energetics Restoration [PDF]

Pharmaceuticals
Background/Objectives: Carvedilol is an adrenergic blocker FDA-approved to improve outcomes in heart failure with reduced ejection fraction. Clinical trials examining whether carvedilol may be cardioprotective in the setting of cancer therapy-induced ...
Asma Boukhalfa, Pei-Tsz Shin, Dawn M. Meola, Ada Yu, Amene Majidipur, Annie Showers, Dylan A. Valencia, Emmanuella F. Akomeah-Sirleaf, Jenica N. Upshaw, Cheryl A. London, Iris Z. Jaffe, David E. Sosnovik, Lakshmi Pulakat, Vicky K. Yang, Howard H. Chen   +14 more
doaj   +2 more sources

Therapeutic Effects of Carvedilol on Intestinal Mucosa in Intestinal Ischemia Reperfusion Injury Model; An Experimental Study [PDF]

Journal of Indian Association of Pediatric Surgeons
Background: Intestinal ischemia–reperfusion (I/R) injury is a critical clinical condition associated with high morbidity and mortality, with acute mesenteric ischemia carrying mortality rates of 60%–80%.
Fatma Tugba Güçlü Güvenç, Özlem Balci, Hilal Nakkas, Habibe Meltem Ozguner, Ismet Faruk Özgüner   +4 more
doaj   +2 more sources

Comparative Study of Selected Excipients’ Influence on Carvedilol Release from Hypromellose Matrix Tablets

Pharmaceutics, 2023
Solid dosage forms based on hypromellose (HPMC) with prolonged/extended drug release are very important from the research and industrial viewpoint. In the present research, the influence of selected excipients on carvedilol release performance from HPMC ...
Tadej Ojsteršek, Grega Hudovornik, Franc Vrečer   +2 more
doaj   +1 more source

A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol at a low dose

Research in Pharmaceutical Sciences, 2022
Background and purpose: The study was aimed at validating a simple, rapid, and low-cost LC-MS/MS method for carvedilol and 4/-hydroxyphenyl carvedilol assay in human plasma. The validated method was applied to investigate the pharmacokinetics after a low
Wanna Eiamart, Nantaporn Prompila, Yaowatree Jumroen, Nonlanee Sayankuldilok, Pajaree Chariyavilaskul, Supeecha Wittayalertpanya   +5 more
doaj   +1 more source

Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect

Journal of Nanobiotechnology, 2021
Background Carvedilol, the anti-hypertensive drug, has poor bioavailability when administered orally. Ethosomes-mediated transdermal delivery is considered a potential route of administration to increase the bioavailability of carvedilol.
Padmanabha Rao Amarachinta, Garima Sharma, Noufel Samed, Ananda Kumar Chettupalli, Madhusudhan Alle, Jin-Chul Kim   +5 more
doaj   +1 more source

Mechanism of carvedilol induced action potential and calcium alternans

Channels, 2022
Carvedilol is a nonspecific β-blocker clinically used for the treatment of cardiovascular diseases but has also been shown to have profound effects on excitation-contraction coupling and Ca signaling at the cellular level. We investigate the mechanism by
Elizabeth Martinez-Hernandez, Giedrius Kanaporis, Lothar A. Blatter   +2 more
doaj   +1 more source

In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches

Scientific Reports, 2023
The pandemic of coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a significant impact on the economy and public health worldwide.
Chunye Zhang, Jiazheng Liu, Yuxiang Sui, Shuai Liu, Ming Yang   +4 more
doaj   +1 more source

Role of GRK5/β-arrestin2 pathway in mediating the cardioprotective effects of carvedilol in 5/6 nephrectomized rats [PDF]

Zagazig University Medical Journal, 2022
Background: Cardiorenal-syndrome is associated with high morbidity and mortality rates. This study tries to clarify the cardio-protective effects of carvedilol in 5/6 nephrectomized rats. Methods: The current study involved five groups of rats: sham, 5/6
Rasha Mohamed, Shimaa Elshazly, Amal Salem, Nevertyty Mahmoud   +3 more
doaj   +1 more source

Long‐Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF ...
Brian Schwartz, Colin Pierce, Christian Madelaire, Morten Schou, Søren Lund Kristensen, Gunnar H. Gislason, Lars Køber, Christian Torp‐Pedersen, Charlotte Andersson   +8 more
doaj   +1 more source

Chitosan as Valuable Excipient for Oral and Topical Carvedilol Delivery Systems

Pharmaceuticals, 2021
Chitosan is a valued excipient due to its biocompatibility properties and increasing solubility of poorly water-soluble drugs. The research presented in this paper concerns the preparation of binary combinations of chitosan (deacetylated chitin) with ...
Szymon Sip, Magdalena Paczkowska-Walendowska, Natalia Rosiak, Andrzej Miklaszewski, Katarzyna Grabańska-Martyńska, Karolina Samarzewska, Judyta Cielecka-Piontek   +6 more
doaj   +1 more source